Summary
3.28 0.02(0.46%)06/28/2024
Fate Therapeutics Inc (FATE)
Fate Therapeutics Inc (FATE)
Key Facts
| 1 Day | 1 Week | 1 Month | 3 Months | 6 Months | 1 Year | 5 Years | All Time |
| 0.46 | -12.53 | -7.61 | -55.40 | -16.75 | -33.06 | -83.84 | -50.45 |
Last 730 data points are shown. To view all data, Upgrade to PRO plan with only $1
| Trading Data | ||
| Close | 3.28 | |
| Open | 3.25 | |
| High | 3.30 | |
| Low | 3.13 | |
| Volume | 972,051 | |
| Change | 0.02 | |
| Change % | 0.46 | |
| Avg Volume (20 Days) | 1,560,273 | |
| Volume/Avg Volume (20 Days) Ratio | 0.62 | |
| 52 Week Range | 1.63 - 8.83 | |
| Price vs 52 Week High | -62.85% | |
| Price vs 52 Week Low | 101.23% | |
| Range | 0.92 | |
| Gap Up/Down | -0.10 | |
Fundamentals | ||
| Market Capitalization (Mln) | 373 | |
| EBIDTA | -181,175,008 | |
| PE Ratio | 0.0000 | |
| PEG Ratio | 0.0000 | |
| WallStreet Target Price | 7.80 | |
| Book Value | 3.7440 | |
| Earnings Per Share | -1.6400 | |
| EPS Estimate Current Quarter | -0.4900 | |
| EPS Estimate Next Quarter | -0.5000 | |
| EPS Estimate Current Year | -1.9600 | |
| EPS Estimate Next Year | -1.8000 | |
| Diluted EPS (TTM) | -1.6400 | |
| Revenues | ||
| Profit Marging | 0.0000 | |
| Operating Marging (TTM) | -26.5288 | |
| Return on asset (TTM) | -0.2084 | |
| Return on equity (TTM) | -0.4207 | |
| Revenue TTM | 6,478,000 | |
| Revenue per share TTM | 0.0650 | |
| Quarterly Revenue Growth (YOY) | -0.9670 | |
| Quarterly Earnings Growth (YOY) | 0.0000 | |
| Gross Profit (TTM) | -224,154,000 | |
| Dividends | ||
| Dividend Share | 0.0000 | |
| Dividend Yield | ||
| Valuations | ||
| Trailing PE | 0.0000 | |
| Forward PE | 0.0000 | |
| Price Sales (TTM) | 0.0000 | |
| Price Book (MRQ) | 1.7851 | |
| Revenue Enterprise Value | 7.0204 | |
| EBITDA Enterprise Value | -2.5897 | |
| Shares | ||
| Shares Outstanding | 113,817,000 | |
| Shares Float | 92,516,933 | |
| Shares Short | 0 | |
| Shares Short (Prior Month) | 0 | |
| Shares Ratio | 0.00 | |
| Short Outstanding (%) | 0.00 | |
| Short Float (%) | 0.22 | |
| Insider (%) | 1.58 | |
| Institutions (%) | 90.13 | |
06/13 08:00 EST - prnewswire.com
FATE SHAREHOLDER ALERT: Kaskela Law LLC Announces Investigation of Fate Therapeutics, Inc. (NASDAQ: FATE) and Encourages Long-Term FATE Investors to Contact the Firm
PHILADELPHIA , June 13, 2024 /PRNewswire/ -- Kaskela Law LLC announces that it is investigating Fate Therapeutics, Inc. (NASDAQ: FATE) ("Fate") on behalf of the company's long-term investors. Recently an amended securities fraud complaint was filed against Fate on behalf of certain investors who purchased shares of the company's stock between August 5, 2020 and January 5, 2023.
FATE SHAREHOLDER ALERT: Kaskela Law LLC Announces Investigation of Fate Therapeutics, Inc. (NASDAQ: FATE) and Encourages Long-Term FATE Investors to Contact the Firm
PHILADELPHIA , June 13, 2024 /PRNewswire/ -- Kaskela Law LLC announces that it is investigating Fate Therapeutics, Inc. (NASDAQ: FATE) ("Fate") on behalf of the company's long-term investors. Recently an amended securities fraud complaint was filed against Fate on behalf of certain investors who purchased shares of the company's stock between August 5, 2020 and January 5, 2023.
06/04 16:01 EST - globenewswire.com
Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
SAN DIEGO, June 04, 2024 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients with cancer and autoimmune disorders, today announced that on June 1, 2024 the Company granted (i) a non-qualified stock option to one newly-hired employee to purchase a total of 65,000 shares of the Company's common stock at an exercise price per share of $3.68, which was the closing price per share of the Company's common stock as reported by NASDAQ on May 31, 2024, the last date preceding the grant effective date for which a closing price was reported, and (ii) restricted stock units (RSUs) representing 14,500 shares of its common stock to three newly-hired non-executive employees. The grants were approved by the Compensation Committee of the Company's Board of Directors and granted under the Company's Amended and Restated Inducement Equity Plan as an inducement material to the new employees entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4). The option will vest over four years, with 25% of the shares underlying the option vesting on the one-year anniversary of the grant date and the remaining 75% percent vesting in approximately equal monthly installments over the following thirty-six months, subject to the employee being continuously employed by the Company through each vesting date. The RSUs will vest over four years, with 25% of the shares underlying each RSU award vesting on each anniversary of the grant date, subject to the employee being continuously employed by the Company through each vesting date.
Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
SAN DIEGO, June 04, 2024 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients with cancer and autoimmune disorders, today announced that on June 1, 2024 the Company granted (i) a non-qualified stock option to one newly-hired employee to purchase a total of 65,000 shares of the Company's common stock at an exercise price per share of $3.68, which was the closing price per share of the Company's common stock as reported by NASDAQ on May 31, 2024, the last date preceding the grant effective date for which a closing price was reported, and (ii) restricted stock units (RSUs) representing 14,500 shares of its common stock to three newly-hired non-executive employees. The grants were approved by the Compensation Committee of the Company's Board of Directors and granted under the Company's Amended and Restated Inducement Equity Plan as an inducement material to the new employees entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4). The option will vest over four years, with 25% of the shares underlying the option vesting on the one-year anniversary of the grant date and the remaining 75% percent vesting in approximately equal monthly installments over the following thirty-six months, subject to the employee being continuously employed by the Company through each vesting date. The RSUs will vest over four years, with 25% of the shares underlying each RSU award vesting on each anniversary of the grant date, subject to the employee being continuously employed by the Company through each vesting date.
05/29 16:01 EST - globenewswire.com
Fate Therapeutics to Present at 2024 Jefferies Global Healthcare Conference
SAN DIEGO, May 29, 2024 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (the “Company” or “Fate Therapeutics”) (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients with cancer and autoimmune diseases, today announced that the Company will present at the 2024 Jefferies Global Healthcare Conference on Wednesday, June 5, 2024 at 3:00 PM ET in New York, New York.
Fate Therapeutics to Present at 2024 Jefferies Global Healthcare Conference
SAN DIEGO, May 29, 2024 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (the “Company” or “Fate Therapeutics”) (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients with cancer and autoimmune diseases, today announced that the Company will present at the 2024 Jefferies Global Healthcare Conference on Wednesday, June 5, 2024 at 3:00 PM ET in New York, New York.
05/20 05:04 EST - https://www.defenseworld.net
Russell Investments Group Ltd. Acquires 59,267 Shares of Fate Therapeutics, Inc. (NASDAQ:FATE)
Russell Investments Group Ltd. increased its holdings in shares of Fate Therapeutics, Inc. (NASDAQ:FATE – Free Report) by 34.0% during the fourth quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 233,748 shares of the biopharmaceutical company’s stock after purchasing an additional 59,267 shares during the period. Russell Investments Group Ltd. owned 0.24% of Fate Therapeutics worth $874,000 as of its most recent SEC filing. A number of other hedge funds and other institutional investors have also recently modified their holdings of FATE. Fox Run Management L.L.C. purchased a new stake in Fate Therapeutics during the third quarter worth $25,000. Vanguard Personalized Indexing Management LLC bought a new stake in Fate Therapeutics during the third quarter valued at about $30,000. Epiq Partners LLC purchased a new position in Fate Therapeutics in the fourth quarter valued at about $38,000. Nisa Investment Advisors LLC raised its holdings in Fate Therapeutics by 1,069.4% in the fourth quarter. Nisa Investment Advisors LLC now owns 16,840 shares of the biopharmaceutical company’s stock worth $63,000 after purchasing an additional 15,400 shares in the last quarter. Finally, Laurion Capital Management LP lifted its position in shares of Fate Therapeutics by 128.6% during the third quarter. Laurion Capital Management LP now owns 35,173 shares of the biopharmaceutical company’s stock valued at $75,000 after buying an additional 19,787 shares during the last quarter. 97.54% of the stock is currently owned by institutional investors. Fate Therapeutics Trading Down 5.8 % Shares of NASDAQ FATE opened at $3.90 on Monday. The company has a 50 day simple moving average of $5.67 and a two-hundred day simple moving average of $4.84. The stock has a market cap of $443.94 million, a price-to-earnings ratio of -2.03 and a beta of 1.80. Fate Therapeutics, Inc. has a 12 month low of $1.63 and a 12 month high of $8.83. Fate Therapeutics (NASDAQ:FATE – Get Free Report) last posted its earnings results on Thursday, May 9th. The biopharmaceutical company reported ($0.47) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($0.47). The company had revenue of $1.93 million during the quarter, compared to the consensus estimate of $0.80 million. Fate Therapeutics had a negative net margin of 2,933.79% and a negative return on equity of 46.49%. During the same period in the previous year, the firm posted ($0.19) earnings per share. Analysts forecast that Fate Therapeutics, Inc. will post -1.9 EPS for the current year. Analyst Upgrades and Downgrades FATE has been the subject of several recent analyst reports. Oppenheimer reiterated a “market perform” rating on shares of Fate Therapeutics in a research note on Tuesday, February 27th. Wedbush reiterated a “neutral” rating and set a $7.00 price objective on shares of Fate Therapeutics in a report on Monday, May 6th. StockNews.com downgraded Fate Therapeutics from a “hold” rating to a “sell” rating in a research note on Friday, May 10th. Morgan Stanley increased their price target on Fate Therapeutics from $3.00 to $7.00 and gave the company an “equal weight” rating in a research note on Tuesday, February 27th. Finally, Barclays upped their price objective on shares of Fate Therapeutics from $6.00 to $10.00 and gave the company an “overweight” rating in a report on Tuesday, February 27th. Two analysts have rated the stock with a sell rating, ten have assigned a hold rating and three have assigned a buy rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Hold” and an average price target of $6.58. Check Out Our Latest Stock Report on Fate Therapeutics Fate Therapeutics Company Profile (Free Report) Fate Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT576 to treat multiple myeloma, and FT522, to treat lymphoma and autoimmune disorders.
Russell Investments Group Ltd. Acquires 59,267 Shares of Fate Therapeutics, Inc. (NASDAQ:FATE)
Russell Investments Group Ltd. increased its holdings in shares of Fate Therapeutics, Inc. (NASDAQ:FATE – Free Report) by 34.0% during the fourth quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 233,748 shares of the biopharmaceutical company’s stock after purchasing an additional 59,267 shares during the period. Russell Investments Group Ltd. owned 0.24% of Fate Therapeutics worth $874,000 as of its most recent SEC filing. A number of other hedge funds and other institutional investors have also recently modified their holdings of FATE. Fox Run Management L.L.C. purchased a new stake in Fate Therapeutics during the third quarter worth $25,000. Vanguard Personalized Indexing Management LLC bought a new stake in Fate Therapeutics during the third quarter valued at about $30,000. Epiq Partners LLC purchased a new position in Fate Therapeutics in the fourth quarter valued at about $38,000. Nisa Investment Advisors LLC raised its holdings in Fate Therapeutics by 1,069.4% in the fourth quarter. Nisa Investment Advisors LLC now owns 16,840 shares of the biopharmaceutical company’s stock worth $63,000 after purchasing an additional 15,400 shares in the last quarter. Finally, Laurion Capital Management LP lifted its position in shares of Fate Therapeutics by 128.6% during the third quarter. Laurion Capital Management LP now owns 35,173 shares of the biopharmaceutical company’s stock valued at $75,000 after buying an additional 19,787 shares during the last quarter. 97.54% of the stock is currently owned by institutional investors. Fate Therapeutics Trading Down 5.8 % Shares of NASDAQ FATE opened at $3.90 on Monday. The company has a 50 day simple moving average of $5.67 and a two-hundred day simple moving average of $4.84. The stock has a market cap of $443.94 million, a price-to-earnings ratio of -2.03 and a beta of 1.80. Fate Therapeutics, Inc. has a 12 month low of $1.63 and a 12 month high of $8.83. Fate Therapeutics (NASDAQ:FATE – Get Free Report) last posted its earnings results on Thursday, May 9th. The biopharmaceutical company reported ($0.47) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($0.47). The company had revenue of $1.93 million during the quarter, compared to the consensus estimate of $0.80 million. Fate Therapeutics had a negative net margin of 2,933.79% and a negative return on equity of 46.49%. During the same period in the previous year, the firm posted ($0.19) earnings per share. Analysts forecast that Fate Therapeutics, Inc. will post -1.9 EPS for the current year. Analyst Upgrades and Downgrades FATE has been the subject of several recent analyst reports. Oppenheimer reiterated a “market perform” rating on shares of Fate Therapeutics in a research note on Tuesday, February 27th. Wedbush reiterated a “neutral” rating and set a $7.00 price objective on shares of Fate Therapeutics in a report on Monday, May 6th. StockNews.com downgraded Fate Therapeutics from a “hold” rating to a “sell” rating in a research note on Friday, May 10th. Morgan Stanley increased their price target on Fate Therapeutics from $3.00 to $7.00 and gave the company an “equal weight” rating in a research note on Tuesday, February 27th. Finally, Barclays upped their price objective on shares of Fate Therapeutics from $6.00 to $10.00 and gave the company an “overweight” rating in a report on Tuesday, February 27th. Two analysts have rated the stock with a sell rating, ten have assigned a hold rating and three have assigned a buy rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Hold” and an average price target of $6.58. Check Out Our Latest Stock Report on Fate Therapeutics Fate Therapeutics Company Profile (Free Report) Fate Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT576 to treat multiple myeloma, and FT522, to treat lymphoma and autoimmune disorders.
05/20 01:38 EST - https://www.defenseworld.net
Fate Therapeutics, Inc. Expected to Post Q2 2024 Earnings of ($0.40) Per Share (NASDAQ:FATE)
Fate Therapeutics, Inc. (NASDAQ:FATE – Free Report) – Research analysts at HC Wainwright raised their Q2 2024 EPS estimates for Fate Therapeutics in a report released on Thursday, May 16th. HC Wainwright analyst R. Burns now expects that the biopharmaceutical company will post earnings per share of ($0.40) for the quarter, up from their previous forecast of ($0.47). HC Wainwright has a “Neutral” rating and a $5.00 price target on the stock. The consensus estimate for Fate Therapeutics’ current full-year earnings is ($1.90) per share. HC Wainwright also issued estimates for Fate Therapeutics’ Q3 2024 earnings at ($0.44) EPS, Q4 2024 earnings at ($0.45) EPS, FY2024 earnings at ($1.75) EPS, Q1 2025 earnings at ($0.46) EPS, Q2 2025 earnings at ($0.47) EPS, Q3 2025 earnings at ($0.49) EPS, Q4 2025 earnings at ($0.50) EPS and FY2025 earnings at $1.93 EPS. Fate Therapeutics (NASDAQ:FATE – Get Free Report) last released its quarterly earnings data on Thursday, May 9th. The biopharmaceutical company reported ($0.47) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.47). Fate Therapeutics had a negative return on equity of 46.49% and a negative net margin of 2,933.79%. The business had revenue of $1.93 million during the quarter, compared to analysts’ expectations of $0.80 million. During the same period in the prior year, the firm posted ($0.19) EPS. Several other research analysts have also recently issued reports on the stock. Oppenheimer restated a “market perform” rating on shares of Fate Therapeutics in a report on Tuesday, February 27th. Needham & Company LLC restated a “hold” rating on shares of Fate Therapeutics in a report on Thursday, April 11th. Morgan Stanley upped their target price on shares of Fate Therapeutics from $3.00 to $7.00 and gave the company an “equal weight” rating in a report on Tuesday, February 27th. Bank of America upped their target price on shares of Fate Therapeutics from $2.00 to $6.00 and gave the company an “underperform” rating in a report on Thursday, March 28th. Finally, Piper Sandler lowered their target price on shares of Fate Therapeutics from $7.00 to $4.00 and set a “neutral” rating for the company in a report on Friday, May 10th. Two research analysts have rated the stock with a sell rating, ten have given a hold rating and three have issued a buy rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of “Hold” and an average price target of $6.58. Check Out Our Latest Analysis on Fate Therapeutics Fate Therapeutics Stock Down 5.8 % Shares of FATE opened at $3.90 on Monday. Fate Therapeutics has a 52-week low of $1.63 and a 52-week high of $8.83. The stock has a 50 day moving average price of $5.67 and a 200 day moving average price of $4.84. The company has a market capitalization of $443.94 million, a price-to-earnings ratio of -2.03 and a beta of 1.80. Hedge Funds Weigh In On Fate Therapeutics A number of large investors have recently bought and sold shares of FATE. Victory Capital Management Inc. increased its holdings in shares of Fate Therapeutics by 22.8% in the 4th quarter. Victory Capital Management Inc. now owns 12,504 shares of the biopharmaceutical company’s stock valued at $47,000 after purchasing an additional 2,322 shares in the last quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. increased its holdings in shares of Fate Therapeutics by 15.1% in the 3rd quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. now owns 60,299 shares of the biopharmaceutical company’s stock valued at $128,000 after purchasing an additional 7,916 shares in the last quarter. Epiq Partners LLC purchased a new position in shares of Fate Therapeutics in the 4th quarter valued at about $38,000. Simplicity Wealth LLC purchased a new position in shares of Fate Therapeutics in the 1st quarter valued at about $81,000. Finally, Fox Run Management L.L.C. purchased a new position in shares of Fate Therapeutics in the 3rd quarter valued at about $25,000. Hedge funds and other institutional investors own 97.54% of the company’s stock. About Fate Therapeutics (Get Free Report) Fate Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT576 to treat multiple myeloma, and FT522, to treat lymphoma and autoimmune disorders.
Fate Therapeutics, Inc. Expected to Post Q2 2024 Earnings of ($0.40) Per Share (NASDAQ:FATE)
Fate Therapeutics, Inc. (NASDAQ:FATE – Free Report) – Research analysts at HC Wainwright raised their Q2 2024 EPS estimates for Fate Therapeutics in a report released on Thursday, May 16th. HC Wainwright analyst R. Burns now expects that the biopharmaceutical company will post earnings per share of ($0.40) for the quarter, up from their previous forecast of ($0.47). HC Wainwright has a “Neutral” rating and a $5.00 price target on the stock. The consensus estimate for Fate Therapeutics’ current full-year earnings is ($1.90) per share. HC Wainwright also issued estimates for Fate Therapeutics’ Q3 2024 earnings at ($0.44) EPS, Q4 2024 earnings at ($0.45) EPS, FY2024 earnings at ($1.75) EPS, Q1 2025 earnings at ($0.46) EPS, Q2 2025 earnings at ($0.47) EPS, Q3 2025 earnings at ($0.49) EPS, Q4 2025 earnings at ($0.50) EPS and FY2025 earnings at $1.93 EPS. Fate Therapeutics (NASDAQ:FATE – Get Free Report) last released its quarterly earnings data on Thursday, May 9th. The biopharmaceutical company reported ($0.47) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.47). Fate Therapeutics had a negative return on equity of 46.49% and a negative net margin of 2,933.79%. The business had revenue of $1.93 million during the quarter, compared to analysts’ expectations of $0.80 million. During the same period in the prior year, the firm posted ($0.19) EPS. Several other research analysts have also recently issued reports on the stock. Oppenheimer restated a “market perform” rating on shares of Fate Therapeutics in a report on Tuesday, February 27th. Needham & Company LLC restated a “hold” rating on shares of Fate Therapeutics in a report on Thursday, April 11th. Morgan Stanley upped their target price on shares of Fate Therapeutics from $3.00 to $7.00 and gave the company an “equal weight” rating in a report on Tuesday, February 27th. Bank of America upped their target price on shares of Fate Therapeutics from $2.00 to $6.00 and gave the company an “underperform” rating in a report on Thursday, March 28th. Finally, Piper Sandler lowered their target price on shares of Fate Therapeutics from $7.00 to $4.00 and set a “neutral” rating for the company in a report on Friday, May 10th. Two research analysts have rated the stock with a sell rating, ten have given a hold rating and three have issued a buy rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of “Hold” and an average price target of $6.58. Check Out Our Latest Analysis on Fate Therapeutics Fate Therapeutics Stock Down 5.8 % Shares of FATE opened at $3.90 on Monday. Fate Therapeutics has a 52-week low of $1.63 and a 52-week high of $8.83. The stock has a 50 day moving average price of $5.67 and a 200 day moving average price of $4.84. The company has a market capitalization of $443.94 million, a price-to-earnings ratio of -2.03 and a beta of 1.80. Hedge Funds Weigh In On Fate Therapeutics A number of large investors have recently bought and sold shares of FATE. Victory Capital Management Inc. increased its holdings in shares of Fate Therapeutics by 22.8% in the 4th quarter. Victory Capital Management Inc. now owns 12,504 shares of the biopharmaceutical company’s stock valued at $47,000 after purchasing an additional 2,322 shares in the last quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. increased its holdings in shares of Fate Therapeutics by 15.1% in the 3rd quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. now owns 60,299 shares of the biopharmaceutical company’s stock valued at $128,000 after purchasing an additional 7,916 shares in the last quarter. Epiq Partners LLC purchased a new position in shares of Fate Therapeutics in the 4th quarter valued at about $38,000. Simplicity Wealth LLC purchased a new position in shares of Fate Therapeutics in the 1st quarter valued at about $81,000. Finally, Fox Run Management L.L.C. purchased a new position in shares of Fate Therapeutics in the 3rd quarter valued at about $25,000. Hedge funds and other institutional investors own 97.54% of the company’s stock. About Fate Therapeutics (Get Free Report) Fate Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT576 to treat multiple myeloma, and FT522, to treat lymphoma and autoimmune disorders.
05/11 18:12 EST - seekingalpha.com
Fate Therapeutics, Inc. (FATE) Q1 2024 Earnings Call Transcript
Fate Therapeutics, Inc. (NASDAQ:FATE ) Q1 2024 Results Conference Call May 9, 2024 5:00 PM ET Company Participants Scott Wolchko - President and CEO Ed Dulac - CFO Bob Valamehr - Chief Research and Development Officer Conference Call Participants Michael Yee - Jefferies Ashiq Mubarack - Citi Jeff LaRosa - Leerink Partners Rohit Bhasin - Morgan Stanley Li Watsek - Cantor Fitzgerald Greg Williams - TD Cowen Carolina Ibanez-Ventoso - Stifel Alex Bouilloux - Barclays Yanan Zhu - Wells Fargo Securities Bill Maughan - Canaccord Genuity Ethan Markowski - Needham & Company Operator Welcome to the Fate Therapeutics First Quarter 2024 Financial Results Conference Call [Operator Instructions]. This call is being webcast live on the Investors section of Fate's Web site at fatetherapeutics.com.
Fate Therapeutics, Inc. (FATE) Q1 2024 Earnings Call Transcript
Fate Therapeutics, Inc. (NASDAQ:FATE ) Q1 2024 Results Conference Call May 9, 2024 5:00 PM ET Company Participants Scott Wolchko - President and CEO Ed Dulac - CFO Bob Valamehr - Chief Research and Development Officer Conference Call Participants Michael Yee - Jefferies Ashiq Mubarack - Citi Jeff LaRosa - Leerink Partners Rohit Bhasin - Morgan Stanley Li Watsek - Cantor Fitzgerald Greg Williams - TD Cowen Carolina Ibanez-Ventoso - Stifel Alex Bouilloux - Barclays Yanan Zhu - Wells Fargo Securities Bill Maughan - Canaccord Genuity Ethan Markowski - Needham & Company Operator Welcome to the Fate Therapeutics First Quarter 2024 Financial Results Conference Call [Operator Instructions]. This call is being webcast live on the Investors section of Fate's Web site at fatetherapeutics.com.
05/09 18:26 EST - zacks.com
Fate Therapeutics (FATE) Reports Q1 Loss, Tops Revenue Estimates
Fate Therapeutics (FATE) came out with a quarterly loss of $0.47 per share in line with the Zacks Consensus Estimate. This compares to loss of $0.19 per share a year ago.
Fate Therapeutics (FATE) Reports Q1 Loss, Tops Revenue Estimates
Fate Therapeutics (FATE) came out with a quarterly loss of $0.47 per share in line with the Zacks Consensus Estimate. This compares to loss of $0.19 per share a year ago.
05/09 16:01 EST - globenewswire.com
Fate Therapeutics Reports First Quarter 2024 Financial Results and Business Updates
First Lupus Patient Treated with FT819 CAR T-cell Product Candidate in Phase 1 Autoimmunity Study; Future Clinical Development of FT819 to Focus Exclusively on Autoimmune Disease
Fate Therapeutics Reports First Quarter 2024 Financial Results and Business Updates
First Lupus Patient Treated with FT819 CAR T-cell Product Candidate in Phase 1 Autoimmunity Study; Future Clinical Development of FT819 to Focus Exclusively on Autoimmune Disease
05/09 08:30 EST - globenewswire.com
Fate Therapeutics Announces First Lupus Patient Treated in Phase 1 Autoimmunity Study of Off-the-shelf FT819 CAR T-cell Program
Pre-treatment Sample of Patient's Blood Showed Rapid and Potent Depletion of CD19+ B Cells in Ex Vivo Cytotoxicity Assay with FT819
Fate Therapeutics Announces First Lupus Patient Treated in Phase 1 Autoimmunity Study of Off-the-shelf FT819 CAR T-cell Program
Pre-treatment Sample of Patient's Blood Showed Rapid and Potent Depletion of CD19+ B Cells in Ex Vivo Cytotoxicity Assay with FT819
05/03 16:30 EST - globenewswire.com
Fate Therapeutics Announces Presentation of FT522 Preclinical Data for Autoimmune Diseases in Late-breaking Abstract at ASGCT Annual Meeting
Off-the-shelf, CD19-targeted CAR NK Cell Product Candidate Drives Rapid and Deep Depletion of SLE Donor CD19+ B cells
Fate Therapeutics Announces Presentation of FT522 Preclinical Data for Autoimmune Diseases in Late-breaking Abstract at ASGCT Annual Meeting
Off-the-shelf, CD19-targeted CAR NK Cell Product Candidate Drives Rapid and Deep Depletion of SLE Donor CD19+ B cells
04/29 16:48 EST - seekingalpha.com
Fate Therapeutics: As Its Rally Fizzles, We May Be Near The Bottom
Fate Therapeutics has a lot of potential in the cell therapy market, with multiple pipeline projects in development. Their flagship allogeneic CAR T-cell project, FT819, has shown promising results in early reports, particularly in patients with B-cell lymphoma. The company is also developing NK cell immunotherapies, with one program, FT522, showing positive results in patients with B-cell lymphoma. However, their cash burn rate remains high, which could be a risk.
Fate Therapeutics: As Its Rally Fizzles, We May Be Near The Bottom
Fate Therapeutics has a lot of potential in the cell therapy market, with multiple pipeline projects in development. Their flagship allogeneic CAR T-cell project, FT819, has shown promising results in early reports, particularly in patients with B-cell lymphoma. The company is also developing NK cell immunotherapies, with one program, FT522, showing positive results in patients with B-cell lymphoma. However, their cash burn rate remains high, which could be a risk.
04/29 12:09 EST - seekingalpha.com
Fate Therapeutics: Looking For A Potential Turnaround In 2024
Fate Therapeutics has faced setbacks, including the termination of a partnership with Janssen Pharmaceuticals, but upcoming clinical milestones could reset the bull thesis. The company's iPSCs technology creates renewable off-the-shelf cell therapies for hematological malignancies and solid tumors. Fate Therapeutics has a healthy cash position and is expected to report positive data from clinical trials, potentially leading to exponential growth and significant market share.
Fate Therapeutics: Looking For A Potential Turnaround In 2024
Fate Therapeutics has faced setbacks, including the termination of a partnership with Janssen Pharmaceuticals, but upcoming clinical milestones could reset the bull thesis. The company's iPSCs technology creates renewable off-the-shelf cell therapies for hematological malignancies and solid tumors. Fate Therapeutics has a healthy cash position and is expected to report positive data from clinical trials, potentially leading to exponential growth and significant market share.
04/22 16:30 EST - globenewswire.com
Fate Therapeutics Announces Presentation of FT819 Proof-of-Concept Data for B cell-mediated Autoimmune Diseases at ASGCT Annual Meeting
Key Therapeutic Mechanisms of Clinical Activity for Autoimmune Diseases, including B cell Depletion, Tissue Infiltration and Immune Reconstitution Data, from Phase 1 Study of FT819 in Relapsed / Refractory B-cell Malignancies to be Highlighted
Fate Therapeutics Announces Presentation of FT819 Proof-of-Concept Data for B cell-mediated Autoimmune Diseases at ASGCT Annual Meeting
Key Therapeutic Mechanisms of Clinical Activity for Autoimmune Diseases, including B cell Depletion, Tissue Infiltration and Immune Reconstitution Data, from Phase 1 Study of FT819 in Relapsed / Refractory B-cell Malignancies to be Highlighted
04/06 03:21 EST - zacks.com
Fate Therapeutics (FATE) Surges 86.4% YTD on Pipeline Progress
Fate Therapeutics (FATE) gains 86.4% on encouraging pipeline progress of its cellular immunotherapies for cancer.
Fate Therapeutics (FATE) Surges 86.4% YTD on Pipeline Progress
Fate Therapeutics (FATE) gains 86.4% on encouraging pipeline progress of its cellular immunotherapies for cancer.
04/02 16:01 EST - globenewswire.com
Fate Therapeutics Reports New Employee Inducement Award Under Nasdaq Listing Rule 5635(c)(4)
SAN DIEGO, April 02, 2024 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients with cancer and autoimmune disorders, today announced that on April 1, 2024 the Company granted restricted stock units (RSUs) representing 6,400 shares of its common stock to one newly-hired non-executive employee. The grant was approved by the Compensation Committee of the Company's Board of Directors and granted under the Company's Amended and Restated Inducement Equity Plan as an inducement material to the new employees entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4). The RSUs will vest over four years, with 25% of the shares underlying each RSU award vesting on each anniversary of the grant date, subject to the employee being continuously employed by the Company through each vesting date.
Fate Therapeutics Reports New Employee Inducement Award Under Nasdaq Listing Rule 5635(c)(4)
SAN DIEGO, April 02, 2024 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients with cancer and autoimmune disorders, today announced that on April 1, 2024 the Company granted restricted stock units (RSUs) representing 6,400 shares of its common stock to one newly-hired non-executive employee. The grant was approved by the Compensation Committee of the Company's Board of Directors and granted under the Company's Amended and Restated Inducement Equity Plan as an inducement material to the new employees entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4). The RSUs will vest over four years, with 25% of the shares underlying each RSU award vesting on each anniversary of the grant date, subject to the employee being continuously employed by the Company through each vesting date.
03/19 08:44 EST - globenewswire.com
Fate Therapeutics Announces Pricing of $100 Million Underwritten Offering and Concurrent Private Placement
SAN DIEGO, March 19, 2024 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (the “Company” or “Fate Therapeutics”) (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients with cancer and autoimmune disorders, today announced the pricing of an underwritten offering of 14,545,454 shares of its common stock at an offering price of $5.50 per share. The offering includes participation from new and existing institutional investors, including Adage Capital Partners LP., Boxer Capital, Deep Track Capital, OrbiMed, Suvretta Capital and a life-sciences focused investor.
Fate Therapeutics Announces Pricing of $100 Million Underwritten Offering and Concurrent Private Placement
SAN DIEGO, March 19, 2024 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (the “Company” or “Fate Therapeutics”) (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients with cancer and autoimmune disorders, today announced the pricing of an underwritten offering of 14,545,454 shares of its common stock at an offering price of $5.50 per share. The offering includes participation from new and existing institutional investors, including Adage Capital Partners LP., Boxer Capital, Deep Track Capital, OrbiMed, Suvretta Capital and a life-sciences focused investor.
03/01 08:00 EST - globenewswire.com
Fate Therapeutics to Present at Upcoming March Investor Conferences
SAN DIEGO, March 01, 2024 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (the “Company” or “Fate Therapeutics”) (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients with cancer and autoimmune disorders, today announced that the Company will participate in the following upcoming investor conferences:
Fate Therapeutics to Present at Upcoming March Investor Conferences
SAN DIEGO, March 01, 2024 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (the “Company” or “Fate Therapeutics”) (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients with cancer and autoimmune disorders, today announced that the Company will participate in the following upcoming investor conferences:
02/27 10:20 EST - zacks.com
Fate Therapeutics (FATE) Q4 Earnings Beat, Revenues Fall Y/Y
Fate Therapeutics (FATE) reports encouraging fourth-quarter results as loss narrows year over year due to lower operating expenses.
Fate Therapeutics (FATE) Q4 Earnings Beat, Revenues Fall Y/Y
Fate Therapeutics (FATE) reports encouraging fourth-quarter results as loss narrows year over year due to lower operating expenses.
02/26 20:25 EST - seekingalpha.com
Fate Therapeutics, Inc. (FATE) Q4 2023 Earnings Call Transcript
Fate Therapeutics, Inc. (FATE) Q4 2023 Earnings Call Transcript
Fate Therapeutics, Inc. (FATE) Q4 2023 Earnings Call Transcript
Fate Therapeutics, Inc. (FATE) Q4 2023 Earnings Call Transcript